No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Wells Fargo Maintains Septerna(SEPN.US) With Buy Rating, Maintains Target Price $43
Septerna | 10-Q: Quarterly report
Septerna | 8-K: Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Express News | Septerna-Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for Hypoparathyroidism, With Data Expected in Mid-2025
TD Cowen Maintains Septerna(SEPN.US) With Buy Rating
Unlock the Full List